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Helicobacter pylori is a microaerophilic bacterium that chronically infects the human gastric 
mucosa. Infections caused by this pathogen are difficult to treat, mainly due to the increased 
resistance of this species to conventional antibiotics. Therefore, it is important to develop 
antibiotic alternative or complementary approaches to tackle H.  pylori infections. 
Bacterio(phages) have proven to be efficient antibacterial agents, however it is very difficult to 
isolate strictly lytic phages infecting H. pylori. Nevertheless, this bacterial species presents 
prophages in their genomes and although strictly lytic phages have been consensually 
preferred for phage therapy purposes, temperate prophages holds a great but an exploited 
potential. 
In the present work, we developed a new PCR-based screening method to detect the presence 
of prophages genes in a set of H. pylori Portuguese clinical strains. The genomes of selected 
strains were then sequenced using a combined Illumina platform and MinION nanopore-based 
sequencing strategy. Prophages’ content was then analysed using the PHASTER tool. After 
sequencing analysis, UV light was used to induce phages, from which one was further 
characterized in terms of morphology, host range, stability on an in vitro gastric model, genome 
analysis and efficacy against a H. pylori culture. 
The complementarity between Illumina and Nanopore results, allowed us to identify a total of 
10 intact, 7 questionable and 47 incomplete prophages on the 14 sequenced strains. One 
predicted intact prophage was induced successfully, and presents a genome length of 31 162 
bp with 37.1 % G+C content. Interestingly, this new podovirus infects five H. pylori strains, and 
in the gastric in vitro model only a small loss of phage titer was observed in the gastric phase, 
suggesting that this phage could be adapted to the stomach environment. Farther, this phage 
demonstrated to be capable of maintaining the H. pylori population at low levels for up to 24 h 
post-infection with MOIs of 0.01, 0.1 and 1.  




Overall, a new PCR screening method was developed to detect prophages on H. pylori and 
positive correlations with sequencing results were observed. Moreover, this new isolated 
phage seems to have therapeutic potential to treat H. pylori gastric infections. 
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